RELA and non-small cell lung carcinoma: It has been documented that the main effectors of the classical, NF-κB1 and RelA (transcription factor P65), as well as of the alternative pathway, NF-κB2 and RelB (transcription factor RelB), are overexpressed and have prognostic value in NSCLC (1–5).